---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-016017"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:36:16.692352+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics announces $46.8M cash, runway into H2 2027, ALSTARS readout Q1 2027

## Summary
- Cash balance of $46.8M as of Dec 31, 2025 (unaudited), with projected runway into second half of 2027.
- Company expects topline data readout from ALSTARS Phase 2 trial in first quarter of 2027.
- Updates conveyed in letter to stockholders dated January 20, 2026.

## SEC filing metadata
- accession: 0001193125-26-016017
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312526016017/0001193125-26-016017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312526016017/d48170d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-016017
- JSON: https://secwatch.observer/filing/0001193125-26-016017.json
- Plain text: https://secwatch.observer/filing/0001193125-26-016017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.